🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsVendor ReviewsHas anyone dealt with telehealth provider comparison?

Has anyone dealt with telehealth provider comparison?

LondonLisa Sun, Apr 6, 2025 at 7:18 AM 9 replies 1,545 viewsPage 1 of 2
This thread is more than 14 months old. Information may be outdated. Consider searching for more recent discussions.
LondonLisa
Member
912
3,456
Mar 2024
London, UK
Apr 6, 2025 at 7:18 AM#1

A reference post rather than a discussion. Corrections are the point; I would rather this be right than mine. It is about cost and coverage, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.

The condition it depends on

Coverage criteria are plan-specific rather than insurer-specific. Two people with the same insurer and different employers have different rules, which is why "my insurer covers it" is not transferable information.

What I am not sure about

So the question, as narrowly as I can put it: what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work. Happy to be told the question itself is wrong.

— LondonLisa · corrections welcome and will be edited into this post with credit
39 9SaraMom3, Dr.MetabolicMD, RetaRick_CA and 36 others
Reply Quote Save Share Report
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Apr 6, 2025 at 8:02 AM#2
LondonLisa said:
Denials are usually procedural rather than clinical, and the order that works reflects that.
LondonLisa said:
...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

38 8andrew_nyc, Dr.EndoEP, GraceAZ_72 and 35 others
Reply Quote Save Share Report
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Apr 6, 2025 at 8:46 AM#3
LondonLisa said:
Denials are usually procedural rather than clinical, and the order that works reflects that.

Pushing back on LondonLisa here. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

37 7COA_Karl, MikeFit_NJ, InsuranceTom and 34 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Apr 6, 2025 at 9:30 AM#4
Dr.GastroMayo said:
The affordability discussion here usually stops at individual tactics.
Dr.GastroMayo said:
...compounded vs brand cost and coverage...

This debate comes up weekly and I think both sides have valid points:

Pro-brand: FDA-approved, manufacturing standards guaranteed, clinical trial data directly applicable

Pro-compounded: 10x cost savings, same active molecule, independent testing available, accessibility

My position: if you can afford brand or have insurance coverage, that's the gold standard. If not, properly tested compounded from a 503B pharmacy is a reasonable alternative. Neither side should shame the other.

36 6hans_munich, jason_sac26, chris_chi24 and 33 others
Reply Quote Save Share Report
sophie_paris
Member
212
890
Nov 2024
Paris, FR
Apr 6, 2025 at 1:38 PM#5
Dr.ReproEndo said:
LondonLisa said: ...regarding the discontinuation data for cost and coverage...

Adding a me-too, because a thread of one person's experience is not much use. Nothing to add that would improve it.

35 5BethLabQueen, ChrisMacros, KetoKyle and 32 others
Reply Quote Save Share Report

Similar Threads

[REVIEW] WWB — 8 months, 6 orders, all Janoshik tested7 replies
[REVIEW] QSC — consistency and pricing, 10+ orders deep5 replies
[REVIEW] GGPeps — 6 orders, all independently tested3 replies
Which vendor should I go with? Side-by-side comparison3 replies
How do you vet a new vendor? My quality checklist9 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register